{
    "clinical_study": {
        "@rank": "23289", 
        "arm_group": [
            {
                "arm_group_label": "Sertaconazole 2% cream", 
                "arm_group_type": "Active Comparator", 
                "description": "2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up"
            }
        ], 
        "brief_summary": {
            "textblock": "Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients\n      with skin alterations associated with atopic dermatitis"
        }, 
        "brief_title": "Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis", 
        "condition": "Skin Alterations Associated With Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent\n\n          -  Atopic Dermatitis Patients with SCORing Atopic Dermatitis (SCORAD) \u2264 40\n\n          -  Atopic lesion localisation: arms; additional legs, neck\n\n        Exclusion Criteria:\n\n          -  SCORAD > 40\n\n          -  Unstable, uncontrolled medical status (e.g. active systemic or topical infection)\n\n          -  Active immunosuppression or cancer\n\n          -  Narcotics- or Alcohol abuse\n\n          -  Participation in another clinical trial until one month prior inclusion\n\n          -  Known allergies against an ingredient of the investigational medicinal product\n\n          -  Different periods of grace for certain pre-treatments, e.g. topical corticosteroids,\n             immune modulating drugs\n\n          -  Pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792713", 
            "org_study_id": "E550-PRU-2012", 
            "secondary_id": "2012-003954-95"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sertaconazole 2% cream", 
                "intervention_name": "Sertaconazole 2% cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Arm", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sertaconazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Skin alterations", 
            "Atopic Dermatitis"
        ], 
        "lastchanged_date": "February 14, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Universit\u00e4tsmedizin Charit\u00e9 Berlin, Abteilung f\u00fcr Dermatologie und Allergologie"
                }, 
                "investigator": {
                    "last_name": "Martin Metz, Prof. Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "48149"
                    }, 
                    "name": "Universit\u00e4tsklinikum M\u00fcnster, Klinik f\u00fcr Hautkrankheiten"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomisierte, Doppelblinde, Plazebo-kontrollierte Pr\u00fcfung Zum Nachweis Der Wirksamkeit Und Der Lokalen Vertr\u00e4glichkeit Einer 2%Igen Sertaconazol-Cr\u00e8me Bei Patienten Mit Atopischer Dermatitis (Abridged)", 
        "other_outcome": {
            "measure": "Change in Transepidermal water loss (TEWL)", 
            "safety_issue": "No", 
            "time_frame": "d1, d14, d28, d42"
        }, 
        "overall_contact": {
            "email": "macheynar.ramos@spirig.ch", 
            "last_name": "Mac Heynar Ramos Frisancho, Dr. med.", 
            "phone": "+41623878869"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Patient Global Assessment (PGA)", 
            "safety_issue": "No", 
            "time_frame": "day 1, day 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792713"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Eczema Area and Severity Index (EASI)", 
                "safety_issue": "No", 
                "time_frame": "day 1, day 28"
            }, 
            {
                "measure": "Change in Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "d1, d28"
            }, 
            {
                "measure": "Change in Patient Benefit Index (PBI)", 
                "safety_issue": "No", 
                "time_frame": "day 1, day 28"
            }
        ], 
        "source": "Spirig Pharma Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spirig Pharma Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}